Retina · 2011 · 31 citations · 13 references
MedicineOphthalmologyPharmacotherapyOcular ImmunologyOcular PharmacologyVisual DisordersCorticosteroid TherapyMacular DisordersMedication Effects On VisionOcular TolerabilityRetinal PharmacotherapyVisual Loss EvaluationAcuity In Macular DiseaseCase Series ReviewCorticosteroid RegimensMedical Records ReviewSystemic Corticosteroid Ocular EffectsTreatment Regimen ModificationVisual Acuity ChartsVisual Outcome Prognosis
PURPOSE: To ascertain the effect of treatment with methotrexate (MTX) on the visual prognosis of birdshot chorioretinopathy (BSCR). METHODS: Retrospective case series of 76 consecutive patients with HLA-A29-positive BSCR, of whom 46 were followed for at least 5 years and 18 for longer than 10 years. A review of the medical records of 76 patients with BSCR. Treatment regimens were subdivided into the following groups: 1) No systemic immunomodulatory treatment; 2) Treatment with systemic corticosteroids; and 3) Treatments which comprised MTX. First, we calculated eye-years for the different therapeutic regimens and second, we subdivided the patients according to their initial treatment regimen and assessed visual outcomes. RESULTS: Mean visual acuity increased over time in the MTX-treated patients; remained unchanged in patients on systemic corticosteroids and decreased in the patients without systemic treatment (yearly change in LogMar -0.020, -0.034 and 0.028 with P = 0.034, P = 0.71 and P = 0.006 respectively). In the group treated initially with MTX, VA gradually increased in contrast to the remaining groups of patients (P = 0.003). CONCLUSION: In this series, treatment comprising MTX showed better visual outcomes than the untreated patients and corticosteroid-based treatment regimens.
13
Methotrexate for Ocular Inflammatory Diseases
Sapna Gangaputra, Craig Newcomb, Teresa L. Liesegang et al. · Ophthalmology · 2009 · 321 citations